Italia markets open in 45 minutes

IMCR Oct 2024 70.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
4,00000,0000 (0,00%)
In data: 11:31AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente4,0000
Aperto4,0000
Denaro1,8000
Domanda5,8000
Prezzo d'esercizio70,00
Scadenza2024-10-18
Min-Max giorno4,0000 - 4,0000
Contratto - Min-MaxN/D
Volume2
Open Interest9
  • GlobeNewswire

    Immunocore announces upcoming presentation and posters at ESMO 2023

    Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a late-breaking abstract in a mini oral session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 07 October 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed

  • GlobeNewswire

    Immunocore to present at upcoming investor conferences

    Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 September 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at the following investor co

  • GlobeNewswire

    Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update

    Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria, Finland, and Israel with additional European launches expected by year-end New Phase 3 Trial for IMC-F106C (PRAME-A02) in first-line cutaneous melanoma (PRISM-MEL301); expect first patient randomized by 1Q 2024 Enrolling patients in monotherapy and combination arms of IMC-F106C in Phase 1/2 trial, including expans